Results 101 to 110 of about 2,007,940 (182)

Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women [PDF]

Clinical Infectious Diseases, 2018
Postmenopausal women have unique sociobiological human immunodeficiency virus (HIV) risks. We evaluated the safety, pharmacokinetics, and acceptability of a microbicide dapivirine (DPV) vaginal ring (VR) versus placebo in postmenopausal women.We enrolled 96 HIV-negative postmenopausal US women in a phase 2a double-blind, randomized (3:1) trial of ...
Beatrice A Chen, Jingyang Zhang, Holly M Gundacker, Craig W Hendrix, Craig J Hoesley, Robert A Salata, Charlene S Dezzutti, Ariane van der Straten, Wayne B Hall, Cindy E Jacobson, Sherri Johnson, Ian McGowan, Annalene M Nel, Lydia Soto-Torres, Mark A Marzinke, B A Chen, C J Hoesley, B A Chen, R A Salata   +18 more
openaire   +2 more sources

Identifying Low-Frequency Tree-Ring Variation

, 1991
I propose an approach to provide 95% confidence intervals for a chronology of low-frequency tree-ring variation so that a level of significance or importance for trends can be inferred.
Sheppard, Paul R.
core   +4 more sources

Attitudes and perceptions towards novel objective measures of ARV-based vaginal ring use: Results from a global stakeholder survey.

PLoS ONE, 2017
Results of recent microbicide and pre-exposure prophylaxis clinical trials have shown adherence to be a significant challenge with new HIV prevention technologies.
Randy M Stalter, Jenae Tharaldson, Derek H Owen, Eunice Okumu, Thomas Moench, Natasha Mack, Elizabeth E Tolley, Kathleen M MacQueen   +7 more
doaj   +1 more source

Transforming PrEP marketing: understanding the place of PrEP in the hearts and minds of adolescent girls and young women in sub‐Saharan Africa

Journal of the International AIDS Society, Volume 28, Issue S2, July 2025.
Abstract Introduction Adolescent girls and young women (AGYW) in sub‐Saharan Africa (SSA) remain one of the populations most affected by HIV. As HIV prevention options expand—such as the introduction of the dapivirine ring, long‐acting injectable cabotegravir and other potential long‐acting methods—alongside oral pre‐exposure prophylaxis (PrEP), AGYW ...
Emily de Lacy Donaldson, Elmari Briedenhann, Patriciah Jeckonia, Casey Bishopp, Anelde Greeff, Definate Nhamo   +5 more
wiley   +1 more source

Advancing the use of Long‐Acting Extended Delivery formulations for HIV prevention in sub‐Saharan Africa: challenges, opportunities, and recommendations

Journal of the International AIDS Society, 2023
Introduction The burden of HIV in sub‐Saharan Africa (SSA) remains unacceptably high, and disproportionately affects girls and women. While the introduction of oral HIV pre‐exposure prophylaxis (PrEP) in 2012 revolutionized HIV prevention, its ...
Nyaradzo M. Mgodi, Grant Murewanhema, Enos Moyo, Chesterfield Samba, Godfrey Musuka, Tafadzwa Dzinamarira, Joelle M. Brown   +6 more
doaj   +1 more source

Review The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors

Viruses, 2014
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs.
Nicolas Sluis-Cremer
doaj   +1 more source

Seizing the moment: the potential of PrEP choice and innovation to transform HIV prevention

Journal of the International AIDS Society, Volume 28, Issue S2, July 2025.
Abstract Introduction The potential of pre‐exposure prophylaxis (PrEP), as a highly effective and empowering HIV prevention intervention, has not yet been realized. Despite the recent acceleration in the scale‐up of oral PrEP, there is a substantial unmet PrEP need, and the world is not on track to meet the 2025 prevention targets.
Heather‐Marie A. Schmidt, Mateo Prochazka, Heather Ingold, Sushena Reza‐Paul, Thato Chidarikire, Irvin Romyco, Michelle Rodolph   +6 more
wiley   +1 more source

Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring

, 2020
Breastfeeding (BF) women are an important population for biomedicalHIV prevention strategies, but they are rarely included in trials. The 25-mg dapivirinevaginal ring (VR) reduced women’s risk of sexually transmitted HIV infection in twophase 3 trials conducted in Africa.
openaire   +2 more sources

Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir

European Journal of Pharmaceutical Sciences, 2010
Dual segment polyurethane intravaginal rings (IVRs) were fabricated to enable sustained release of antiretroviral agents dapivirine and tenofovir to prevent the male to female sexual transmission of the human immunodeficiency virus. Due to the contrasting hydrophilicity of the two drugs, dapivirine and tenofovir were separately formulated into polymers
Todd J, Johnson, Kavita M, Gupta, Judit, Fabian, Theodore H, Albright, Patrick F, Kiser   +4 more
openaire   +2 more sources

Incremental cost per HIV infection averted by use of the dapivirine ring in South Africa (2018–2035).

, 2019
Incremental cost per HIV infection averted by use of the dapivirine ring in South Africa (2018–2035).
Carel Pretorius (238011), Kristine Torjesen (6883256), Robert Glaubius (6883253), Meghan Reidy (6883250), Katharine Kripke (559963), Elizabeth Gardiner (222246)   +5 more
core   +1 more source